Pharvaris (NASDAQ:PHVS) Insider Sells $10,200.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Peng Lu sold 300 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $34.00, for a total transaction of $10,200.00. Following the transaction, the insider owned 65,631 shares of the company’s stock, valued at approximately $2,231,454. This trade represents a 0.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Peng Lu also recently made the following trade(s):

• On Wednesday, April 29th, Peng Lu sold 3,733 shares of Pharvaris stock. The shares were sold at an average price of $30.06, for a total transaction of $112,213.98.
• On Thursday, April 30th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $30.24, for a total transaction of $453,600.00.
• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total transaction of $210,380.05.

Pharvaris Stock Performance

NASDAQ PHVS opened at $33.30 on Friday. The stock has a market capitalization of $2.18 billion, a P/E ratio of -10.47 and a beta of -2.35. Pharvaris N.V. has a 1 year low of $16.72 and a 1 year high of $35.33. The business’s fifty day moving average is $30.47 and its two-hundred day moving average is $27.93.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. On average, research analysts forecast that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its stake in shares of Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the period. Legal & General Group Plc boosted its stake in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares in the last quarter. Amundi grew its position in Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after acquiring an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after acquiring an additional 7,879 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Citizens Jmp cut their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Wolfe Research started coverage on Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective for the company. UBS Group set a $74.00 target price on shares of Pharvaris in a research report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $49.64.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.